NASDAQ · Biotechnology

KALA (KALA) Stock

$0.76 +3.59% NASDAQ: KALA Healthcare

Valuation

MetricValue
Price$0.76
Market Cap$14.62M
P/E Ratio-0.76
P/B Ratio7.93
P/S Ratio0.00
EPS (TTM)$-3.31
52-Week High$1030.00
52-Week Low$0.61
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-385.71%
ROA-300.00%
ROCE-557.14%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$4.0M$0$0$0
Operating Profit$-109.0M$-81.0M$-39.0M$-40.0M$-39.0M
Net Profit$-143.0M$-45.0M$-42.0M$-39.0M$-27.0M
EPS$-109.35$-29.48$-17.35$-6.98$-3.31
Op Margin-973.6%-2090.3%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$139.0M$87.0M$56.0M$55.0M$9.0M
Total Liabilities$123.0M$68.0M$48.0M$43.0M$2.0M
Cash$92.0M$70.0M$51.0M$51.0M$8.0M
Borrowings$80.0M$43.0M$36.0M$32.0M$0

Latest News

KALA BIO: Q1 Earnings Snapshot Associated Press · May 15, 2026 KALA BIO Announces Reverse Stock Split GlobeNewswire · May 7, 2026 Aterian, Inc. Announces Definitive Agreement for the Sale of its Marquee Brand Portfolio for $18 Million Subject to Adjustments GlobeNewswire · Apr 28, 2026 Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine GlobeNewswire · Apr 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-108.0M$-79.0M$-28.0M$-29.0M$-32.0M
Investing Cash Flow$70.0M$62.0M$-1.0M$0$0
Financing Cash Flow$2.0M$0$-2.0M$0$0
Net Cash Flow$5.0M$-24.0M$-20.0M$0$-44.0M
Free Cash Flow$-109.0M$-79.0M$-29.0M$-30.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-47.16%
Quick Ratio7.91
Interest Coverage-13.00
Return 1Y-99.62%
Return 3Y-99.86%
Return 5Y-99.99%

Ownership

Insiders Held1.29%
Institutions Held0.64%
Institutions Float Held0.65%
Institutional HolderSharesReport Date
Renaissance Technologies, LLC8,3502026-03-31
Citadel Advisors Llc5,6332026-03-31
Geode Capital Management, LLC5,2212026-03-31
Virtu Financial LLC3,0442026-03-31
Adar1 Capital Management, LLC 2,8302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABPAbpro Corporation $0.52 — -0.02 $1.06M 0.00%
AIM $0.24 -5.84% -0.09 $801193 0.00%
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
IBO $0.43 -2.27% -1.61 $5.38M 0.00%

About KALA

KALA is led by CEO Avi Minkowitz, employs 38 people, headquartered in US, publicly traded since 2017.

KALA stock trades at $0.76 with a market capitalization of $14.62M. The stock is valued at a price-to-earnings (P/E) ratio of -0.76, price-to-book of 7.93, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.61 and $1030.00, and currently trades 99.9% below its 52-week high.

On profitability, KALA generates a return on equity (ROE) of -385.71%, return on capital employed of -557.14%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides